Search for Topics:
Title/Keyword
Journal
Submission Status
Category
 
 
Topics
Cancer Genomics: Emerging Trends and Technological Advances
Submit your Manuscript Submit your Abstract Propose a Topic

Topic Menu

► Topic Menu

Topic Editors

División de Genética, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico
Dr. Luis Eduardo Figuera Villanueva
Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico
Department of Cardiovascular Research, Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
share announcement

Cancer Genomics: Emerging Trends and Technological Advances

Abstract submission deadline
31 March 2027
Manuscript submission deadline
31 May 2027
Viewed by
475

Topic Information

Dear Colleagues,

We are pleased to announce the new Topic “Cancer Genomics: Emerging Trends and Technological Advances”. This initiative aims to foster and integrate cutting-edge research in cancer genetics and genomics, addressing the complexity and heterogeneity of this disease. In recent years, the incorporation of novel technologies into cancer genomics has significantly expanded our understanding of tumor biology, enabling advances in diagnosis, prognosis, and therapeutic strategies. Therefore, this Topic seeks to promote and gather high-quality research that leverages innovative approaches to investigate the genetic and genomic underpinnings of cancer. We particularly welcome original studies and reviews that integrate data from next-generation sequencing (NGS), computational analyses, multi-omics profiling, machine learning algorithms, and other advanced tools to explore cancer susceptibility, progression, and treatment response. By highlighting emerging technologies and interdisciplinary approaches, we hope this Topic will contribute to a more comprehensive and precise understanding of cancer biology and support the development of personalized medicine strategies. We look forward to your valuable contributions.

Dr. Martha Patricia Gallegos-Arreola
Dr. Luis Eduardo Figuera Villanueva
Dr. Hector Barajas-Martinez
Topic Editors

Keywords

  • cancer genomics
  • next-generation sequencing
  • precision oncology
  • bioinformatics
  • multi-omics integration
  • machine learning

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Biomedicines
biomedicines 		3.9 6.8 2013 17 Days CHF 2600 Submit
Cancers
cancers 		4.4 8.8 2009 20.3 Days CHF 2900 Submit
Current Oncology
curroncol 		3.4 4.9 1994 21.5 Days CHF 2200 Submit
Journal of Clinical Medicine
jcm 		2.9 5.2 2012 17.7 Days CHF 2600 Submit
Onco
onco 		- - 2021 20.7 Days CHF 1000 Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

  1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
  2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
  3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
  4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
  5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (1 paper)

Order results
Result details
Journals
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
14 pages, 1354 KB  
Article
CRISPR with a Double Mismatch Guide RNA Enhances Detection Sensitivity for Low-Frequency Single-Base EGFR Mutation in Circulating Cell-Free DNA of Lung Cancer Patients
by Kyung Wook Been, Seunghun Kang, Taegeun Bae, Sumin Hong, Garyeong Kim, Junho K. Hur, Woochang Hwang and Boksoon Chang
Cancers 2025, 17(20), 3343; https://doi.org/10.3390/cancers17203343 - 16 Oct 2025
Viewed by 182
Abstract
Background/Objectives: Liquid biopsy using cfDNA has emerged as a promising, minimally invasive alternative to traditional tissue biopsy for detecting cancer-associated mutations. However, the extremely low proportion of mutant DNA in cfDNA poses a major challenge for accurate detection, especially when using conventional sequencing [...] Read more.
Background/Objectives: Liquid biopsy using cfDNA has emerged as a promising, minimally invasive alternative to traditional tissue biopsy for detecting cancer-associated mutations. However, the extremely low proportion of mutant DNA in cfDNA poses a major challenge for accurate detection, especially when using conventional sequencing methods. To address this limitation, we sought to develop a highly sensitive diagnostic strategy to selectively enrich rare mutant sequences and improve the detection of clinically important mutations in patients with NSCLC. Methods: We established a CRISPR/Cas12a-based diagnostic system designed to selectively cleave WT DNA, thereby increasing the relative abundance of mutant DNA in cfDNA samples. Following Cas12a-mediated WT cleavage, the remaining DNA was subjected to PCR amplification for mutation identification. The system was applied to plasma cfDNA from blood samples of 48 NSCLC patients to evaluate its ability to detect two major EGFR mutations: L858R and exon 19 deletion. Results: The CRISPR/Cas12a-based diagnostic system effectively identified low-frequency EGFR mutations in cfDNA. Specifically, all 7 L858R-positive samples and 6 out of 11 samples harboring exon 19 deletions—previously validated through tissue biopsy—were successfully detected. This demonstrated a high degree of concordance between our liquid biopsy approach and conventional diagnostic methods. Conclusions: Our findings highlight the potential of the CRISPR/Cas12a-based mutation enrichment system as a powerful tool for detecting rare oncogenic mutations in liquid biopsy samples. This technique enhances diagnostic sensitivity and could be broadly applicable for the non-invasive detection of various genetic alterations in cancer and other diseases. Full article
(This article belongs to the Topic Cancer Genomics: Emerging Trends and Technological Advances)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop